MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Kodu・Aktsiate loetelu・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Suletud

SektorTervishoid

69.47 0.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

69.47

Max

69.47

Põhinäitajad
By Trading Economics
Sissetulek	-5.6M -82M
Müük	-8.7M 2.8M
Kasumimarginaal	-2,973.046
Töötajad	225
EBITDA	5.2M -79M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+67.24% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	27. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	1.6B 5.8B
Eelmine avamishind	69.15
Eelmine sulgemishind	69.47

Uudiste sentiment

By Acuity

20%

80%

30 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

28.34 / 33.56 Toetus ja vastupanu

Kymera Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. dets 2025, 08:30 UTC

Omandamised, ülevõtmised, äriostud

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Kymera Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

67.24% tõus

12 kuu keskmine prognoos

Keskmine 116.3 USD 67.24%

Kõrge 138 USD

Madal 90 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Kymera Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

22 ratings

Osta

Hoia

Müü

Põhineb 22 analüütiku instrumendi Kymera Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

28.34 / 33.56Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

30 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.